Detailed Information

Cited 9 time in webofscience Cited 1 time in scopus
Metadata Downloads

Expert Consensus Recommendations on Biomarker Testing in Metastatic and Nonmetastatic NSCLC in Asia

Authors
Mitsudomi, T[Mitsudomi, Tetsuya]Tan, D[Tan, Daniel]Yang, JCH[Yang, James Chih-Hsin]Ahn, MJ[Ahn, Myung-Ju]Batra, U[Batra, Ullas]Cho, BC[Cho, Byoung-Chul]Cornelio, G[Cornelio, Gerardo]Lim, T[Lim, Tony]Mok, T[Mok, Tony]Prabhash, K[Prabhash, Kumar]Reungwetwattana, T[Reungwetwattana, Thanyanan]Ren, SX[Ren, Sheng-Xiang]Singh, N[Singh, Navneet]Toyooka, S[Toyooka, Shinichi]Wu, YL[Wu, Yi-Long]Yang, PC[Yang, Pan-Chyr]Yatabe, Y[Yatabe, Yasushi]
Issue Date
Apr-2023
Publisher
ELSEVIER SCIENCE INC
Keywords
Non-small cell lung cancer; ctDNA; Biomarkers; Adenocarcinoma; Squamous carcinoma; Liquid biopsy
Citation
JOURNAL OF THORACIC ONCOLOGY, v.18, no.4, pp.436 - 446
Indexed
SCIE
SCOPUS
Journal Title
JOURNAL OF THORACIC ONCOLOGY
Volume
18
Number
4
Start Page
436
End Page
446
URI
https://scholarworks.bwise.kr/skku/handle/2021.sw.skku/102829
DOI
10.1016/j.jtho.2022.10.021
ISSN
1556-0864
Abstract
Introduction: Most published guidelines for genomic biomarker testing in NSCLC reflect the disease epidemiology and treatments readily available in Europe and North America. Nevertheless, 60% of annual global NSCLC cases occur in Asia, where patient characteristics, tumor molecular profiles, and treatments vary greatly from the Western world. For example, mutations in the EGFR occur at a higher prev-alence in Asia than in other world regions. Although medical associations such as the International Association for the Study of Lung Cancer, European Society for Medical Oncology, and American Society of Clinical Oncology have described principles for tumor genomic biomarker testing in NSCLC, there is a need for recommendations specific for Asia.Methods: This report provides consensus recommenda-tions for NSCLC biomarker testing from Asian lung cancer experts for clinicians working in Asia to improve patient care. Biomarker testing approaches for actionable genetic alterations in EGFR, ALK, ROS1, and others are discussed.Results: These recommendations are divided into non -metastatic and metastatic forms of adenocarcinoma and squamous cell carcinoma. Owing to the higher prevalence of EGFR mutations in Asia, the experts emphasized the need for EGFR testing to include not just common mutations (exon 19 deletions and L858R substitutions) but also other uncommon EGFR mutations. In addition to the assessment of biomarkers in the tumor tissue, the role of assessing tumor biomarkers by liquid biopsy is discussed.Conclusion: This consensus provides practical recommen-dations for biomarker testing in nonmetastatic and meta-static Asian NSCLC patients.(c) 2022 International Association for the Study of Lung Cancer. Published by Elsevier Inc. All rights reserved.
Files in This Item
There are no files associated with this item.
Appears in
Collections
Medicine > Department of Medicine > 1. Journal Articles

qrcode

Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.

Related Researcher

Researcher AHN, MYUNG JU photo

AHN, MYUNG JU
Medicine (Medicine)
Read more

Altmetrics

Total Views & Downloads

BROWSE